<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - TACROLIMUS</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>TACROLIMUS</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#drugAction" data-toggle="tab">Drug action</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#nationalFunding" data-toggle="tab">National funding/access decisions</a></li>
          <li><a href="#importantSafetyInformation" data-toggle="tab">Important safety information</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#conceptionAndContraception" data-toggle="tab">conception and contraception</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#unlicensedUse" data-toggle="tab">Unlicensed use</a></li>
          <li><a href="#allergyAndCrossSensitivity" data-toggle="tab">Allergy and cross sensitivity</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Short-term treatment of moderate to severe atopic eczema (including flares) in patients unresponsive to, or intolerant of conventional therapy</span>,
            </h4>
            <p class="specificity"><span class="route">To the skin</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Apply twice daily until lesion clears (consider other treatment if eczema worsens or no improvement after 2 weeks), initially 0.1% ointment to be applied thinly, reduce frequency to once daily or strength of ointment to 0.03% if condition allows.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Prevention of flares in patients with moderate to severe atopic eczema and 4 or more flares a year who have responded to initial treatment with topical tacrolimus</span>,
            </h4>
            <p class="specificity"><span class="route">To the skin</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Apply twice weekly, 0.1% ointment to be applied thinly, with an interval of 2&#8211;3 days between applications, use short-term treatment regimen during an acute flare; review need for preventative therapy after 1 year.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Short-term treatment of facial, flexural, or genital psoriasis in patients unresponsive to, or intolerant of other topical therapy</span>,
            </h4>
            <p class="specificity"><span class="route">To the skin</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Apply twice daily until symptoms resolve, 0.1% ointment to be applied thinly, reduce to once daily or switch to 0.03% ointment if condition allows, maximum duration of treatment 4 weeks.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>


      <section class="tab-pane" id="drugAction">
        <h2>Drug action</h2>

            <section class="drugAction">
              <p>Tacrolimus is a calcineurin inhibitor.</p>
            </section>
      </section>

      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">systemic</ph> use</h3>
              <p>Avoid unless potential benefit outweighs risk&#8212;crosses the placenta and risk of premature delivery, intra-uterine growth restriction, and hyperkalaemia.</p>
            </section>
            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">topical</ph> use</h3>
              <p>Manufacturer advises avoid unless essential; toxicity in <i>animal</i> studies following systemic administration.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="doseAdjustments">
              <h3 class="specificity">With <ph outputclass="route">systemic</ph> use</h3>
              <p>Dose reduction may be necessary in severe impairment.</p>
            </section>
      </section>


      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

        
          <h3>Specific side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> acne, alopecia, anaemia, anorexia, anxiety, arthralgia, ascites, bile-duct abnormalities, bloating, blood disorders, cholestasis, confusion, constipation, depression, diarrhoea, dizziness, dyspepsia, dyspnoea, electrolyte disturbances, flatulence, gastro-intestinal inflammation, gastro-intestinal perforation, gastro-intestinal ulceration, haemorrhage, headache, hepatic dysfunction, hyperglycaemia, hyperkalaemia, hypertension, hyperuricaemia, hypokalaemia, impaired hearing, ischaemic events, jaundice, leucopenia, mood changes, muscle cramp, nausea, oedema, pancytopenia, paraesthesia, parenchymal lung disorders, peripheral neuropathy, photophobia, pleural effusion, psychosis, renal failure, renal impairment, renal tubular necrosis, seizures, sleep disturbances, sweating, tachycardia, thrombocytopenia, thromboembolic events, tinnitus, tremor, urinary abnormalities, visual disturbances, vomiting, weight changes, application-site infections, application-site reactions, herpes simplex infection, irritation (at application-site), Kaposi&#8217;s varicelliform eruption, pain at application-site, rash,
              </p>
              <p>
                <strong>uncommon:</strong> amnesia, arrhythmia, cardiac arrest, cardiomyopathy, cataract, cerebrovascular accident, coagulation disorders, coma, dermatitis, dysmenorrhoea, encephalopathy, gastro-intestinal reflux disease, heart failure, hypertonia, hypoglycaemia, influenza-like symptoms, palpitation, pancreatitis, paralysis, paralytic ileus, peritonitis, photosensitivity, respiratory failure, speech disorder, acne,
              </p>
              <p>
                <strong>rare:</strong> blindness, dehydration, hirsutism, pericardial effusion, posterior reversible encephalopathy syndrome, respiratory distress syndrome, thrombotic thrombocytopenic purpura, toxic epidermal necrolysis,
              </p>
              <p>
                <strong>veryRare:</strong> haemorrhagic cystitis, myasthenia, Stevens-Johnson syndrome,
              </p>
              <p>
                <strong>notKnown:</strong> agranulocytosis, haemolytic anaemia, pure red cell aplasia, cutaneous lymphoma, malignancies, other types of lymphomas, rosacea, skin malignancy,
              </p>
        
            <section class="advice">
              <h3 class="specificity">With <ph outputclass="route">systemic</ph> use</h3>
                <p class="title">Cardiomyopathy</p>
              <p>Cardiomyopathy has been reported in children. Patients should be monitored by echocardiography for hypertrophic changes&#8212;consider dose reduction or discontinuation if these occur.</p>
            </section>
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use</h3>
              <p>For <i>intravenous infusion</i> (<i>Prograf</i>
            <tm tmtype="reg"/>); give continuously in Glucose 5% <i>or</i> Sodium Chloride 0.9%. Dilute concentrate in infusion fluid to a final concentration of 4&#8211;100&#8239;micrograms/mL; give over 24 hours.</p><p>Tacrolimus is incompatible with PVC.</p>
            </section>
      </section>

      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="generalPatientAdvice">
              <p>Avoid excessive exposure to UV light including sunlight.</p>
            </section>
      </section>

      <section class="tab-pane" id="nationalFunding">
        <h2>National funding/access decisions</h2>

            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA82</h3>
              <p outputclass="specificity">With <ph outputclass="route">topical</ph> use</p> <p outputclass="title">Tacrolimus and pimecrolimus for atopic eczema (August 2004)</p> <p>Topical tacrolimus is an option for atopic eczema not controlled by maximal topical corticosteroid treatment or if there is a risk of important corticosteroid side-effects (particularly skin atrophy).</p> <p>Topical tacrolimus is recommended for moderate to severe atopic eczema in adults and children over 2 years.Tacrolimus should be used within its licensed indications.</p><xref format="html" href="http://www.nice.org.uk/TA82">www.nice.org.uk/TA82</xref>
                <a href="http://www.nice.org.uk/TA82" target="_blank">www.nice.org.uk/TA82</a>
            </section>
      </section>

      <section class="tab-pane" id="importantSafetyInformation">
        <h2>Important safety information</h2>

            <section class="importantSafetyInformation">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use</h3>
                <p class="title">Oral tacrolimus products: prescribe and dispense by brand name only, to minimise the risk of inadvertent switching between products, which has been associated with reports of toxicity and graft rejection (June 2012)</p>
              <p>Inadvertent switching between oral tacrolimus products has been associated with reports of toxicity and graft rejection. To ensure maintenance of therapeutic response when a patient is stabilised on a particular brand, oral tacrolimus products should be prescribed and dispensed by brand name only.</p><ul>
            <li>
            <i>Adoport</i>
            <tm tmtype="reg"/>, <i>Prograf</i>
            <tm tmtype="reg"/>, <i>Capexion</i>
            <tm tmtype="reg"/>, <i>Tacni</i>
            <tm tmtype="reg"/>, and <i>Vivadex</i>
            <tm tmtype="reg"/> are immediate-release capsules that are taken twice daily, once in the morning and once in the evening;</li>
            <li>
            <i>Modigraf</i>
            <tm tmtype="reg"/> granules are used to prepare an immediate-release oral suspension which is taken twice daily, once in the morning and once in the evening;</li>
            <li>
            <i>Advagraf</i>
            <tm tmtype="reg"/> is a prolonged-release capsule that is taken once daily in the morning.</li>
            </ul><p>Switching between tacrolimus brands requires careful supervision and therapeutic monitoring by an appropriate specialist.</p>
            </section>
      </section>

      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            UV light (avoid excessive exposure to sunlight and sunlamps)
          </li>
        </ul>
        <ul>
          <li>
              <strong>With systemic use:</strong>
            increased risk of infections
          </li>
          <li>
              <strong>With systemic use:</strong>
            lymphoproliferative disorders
          </li>
          <li>
              <strong>With systemic use:</strong>
            malignancies
          </li>
          <li>
              <strong>With systemic use:</strong>
            neurotoxicity
          </li>
          <li>
              <strong>With systemic use:</strong>
            QT-interval prolongation
          </li>
        </ul>
      </section>

      <section class="tab-pane" id="conceptionAndContraception">
        <h2>Advice regarding conception and contraception</h2>

            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">systemic</ph> use</h3>
              <p>Exclude pregnancy before treatment.</p>
            </section>
      </section>

      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

          <h3>Therapeutic drug monitoring</h3>
        
            <section class="therapeuticDrugMonitoring">
              <h3 class="specificity">With <ph outputclass="route">systemic</ph> use</h3>
              <p>After initial dosing, and for maintenance treatment, tacrolimus doses should be adjusted according to whole-blood concentration.</p><p>Monitor whole blood-tacrolimus trough concentration (especially during episodes of diarrhoea)&#8212;consult local treatment protocol for details.</p>
            </section>
        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <h3 class="specificity">With <ph outputclass="route">systemic</ph> use</h3>
              <p>Monitor blood pressure, ECG (for hypertrophic changes&#8212;risk of cardiomyopathy), fasting blood-glucose concentration, haematological and neurological (including visual) and coagulation parameters, electrolytes, hepatic and renal function.</p>
            </section>
      </section>

      <section class="tab-pane" id="unlicensedUse">
        <h2>Unlicensed use</h2>

            <section class="unlicensedUse">
              <h3 class="specificity">With <ph outputclass="route">topical</ph> use</h3>
              <p>Short-term treatment of facial, flexural, or genital psoriasis is unlicensed.</p>
            </section>
      </section>









      <section class="tab-pane" id="allergyAndCrossSensitivity">
        <h2>Advice regarding allergies and cross sensitivities</h2>

            <section class="contraindications">
              <p>Contraindicated if history of hypersensitivity to macrolides.</p>
            </section>
        
      </section>

      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of TACROLIMUS</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            oral suspension,
            paste,
            oral solution,
            mouthwash,

            <div id="PHP108008"><a href="../medicinalForm/PHP108008.html" data-target="#PHP108008" data-action="load">Modified-release tablet</a></div>
            <div id="PHP75294"><a href="../medicinalForm/PHP75294.html" data-target="#PHP75294" data-action="load">Capsule</a></div>
            <div id="PHP75315"><a href="../medicinalForm/PHP75315.html" data-target="#PHP75315" data-action="load">Modified-release capsule</a></div>
            <div id="PHP75321"><a href="../medicinalForm/PHP75321.html" data-target="#PHP75321" data-action="load">Granules</a></div>
            <div id="PHP75309"><a href="../medicinalForm/PHP75309.html" data-target="#PHP75309" data-action="load">Solution for infusion</a></div>
            <div id="PHP75303"><a href="../medicinalForm/PHP75303.html" data-target="#PHP75303" data-action="load">Ointment</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
